Ad26.ENVA.01 Mucosal/IPCAVD003

A Phase 1 Randomized, Double-Blind, Placebo Controlled Clinical Trial to Evaluate the Safety, Mucosal Immunogenicity and Innate Immune Responses of Recombinant Adenovirus Serotype 26 HIV-1 Vaccine (Ad26.ENVA.01) in Healthy, HIV-1 Uninfected Adults (Ad26.ENVA.01 (rAd26) HIV-1 Mucosal/IPCAVD-003 Vaccine Study)

Trial Details:

I Ongoing
National Institute of Allergy and Infectious Diseases (NIAID)
Ad26.EnvA-01 Ad26 Env A
Ad26.EnvA-01 Viral Vector - Adeno
USA 24